Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Artis Labs
AddedMar 19, 2024
UpdatedJul 16, 2026
Artis Labs

Artis Labs

Operating

Investing in tech and healthcare sectors for US customers.

Location
San Francisco, CA, US
Founded
2001
Firm
Compare
Portfolio
Employees
Website

Investments

Unnatural Products
Unnatural Products

Total Raised

$38M

Rounds

4

Series A$32MDecember 2023
Inceptive
Inceptive

Total Raised

$120M

Rounds

2

Series A$100MSeptember 2023
Ozlo Sleep
Ozlo Sleep

Total Raised

$10M

Rounds

1

Series A$10MAugust 2023
Affect Therapeutics
Affect Therapeutics

Total Raised

$23M

Rounds

4

Series A$16MJuly 2023
Series AFebruary 2023
Range Biotechnologies
Range Biotechnologies

Total Raised

$5.2M

Rounds

2

Seed$5.2MJune 2023
Siren Biotechnology
Siren Biotechnology

Total Raised

$4M

Rounds

2

SeedMay 2023
Outpace Bio
Outpace Bio

Total Raised

$55M

Rounds

2

Series A$25MMarch 2023
Transparent Health Marketplace
Transparent Health Marketplace

Total Raised

$41M

Rounds

3

Series UnknownJanuary 2023
Second Front Systems
Second Front Systems

Total Raised

$82.1M

Rounds

7

Series A$32MDecember 2022
Power Life Science
Power Life Science

Total Raised

$18.9M

Rounds

2

Seed$7MAugust 2022
Replay
Replay

Total Raised

$55M

Rounds

2

Series A$55MJuly 2022
Cartography Biosciences
Cartography Biosciences

Total Raised

$57M

Rounds

2

Series A$57MJuly 2022
Locus Biosciences
Locus Biosciences

Total Raised

$118.7M

Rounds

10

Series B$35MMay 2022
Cerebral
Cerebral

Total Raised

$462M

Rounds

4

Series C$300MDecember 2021
Series B$127MJune 2021
Freenome
Freenome

Total Raised

$1.1B

Rounds

8

Series D$300MDecember 2021
Meomind
Meomind

Total Raised

$1M

Rounds

1

Pre-Seed$1MDecember 2021
RAD AI
RAD AI

Total Raised

$43.1M

Rounds

13

Series A$25MNovember 2021
Delix Therapeutics
Delix Therapeutics

Total Raised

$118.3M

Rounds

6

Series A$70MSeptember 2021
MycoMedica Life Sciences
MycoMedica Life Sciences

Total Raised

$68M

Rounds

3

Series AJuly 2021
Glyphic Biotechnologies
Glyphic Biotechnologies

Total Raised

$10.6M

Rounds

10

Seed$6MJuly 2021
Activ Surgical
Activ Surgical

Total Raised

$100.4M

Rounds

6

Series B$45MJuly 2021
Athena Club
Athena Club

Total Raised

$52.3M

Rounds

3

Series A$15MMay 2021
ViaCyte
ViaCyte
Public

Total Raised

$235.5M

Rounds

15

Series DApril 2021